- Messages
- 890
- Reaction score
- 2
- Points
- 0
MORRISTOWN, N.J., Sept. 13, 2011 /PRNewswire/ Watson Laboratories, Inc. has confirmed today that it has launched Levetiracetam Extended-Release 500 mg and 750 mg tablets – the generic version of Keppra XR® – following approval of the Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA).
Watson has begun shipping the product today. Keppra XR® is indicated to treat partial onset seizures in people 16 years of age and older with epilepsy.
For further information, click on: http://finance.yahoo.com/news/Watson-Launches-Generic-prnews-2763217451.html?x=0&.v=1
Watson has begun shipping the product today. Keppra XR® is indicated to treat partial onset seizures in people 16 years of age and older with epilepsy.
For further information, click on: http://finance.yahoo.com/news/Watson-Launches-Generic-prnews-2763217451.html?x=0&.v=1
Last edited: